Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

NCT00720629 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

8

Enrollment

OTHER

Sponsor class

Conditions

Graft Versus Host Disease

Interventions

DRUG: Visilizumab
DRUG: Tacrolimus
DRUG: Methotrexate
DRUG: Antithymocyte globulin (ATG)
DRUG: Tacrolimus
DRUG: Methotrexate

Sponsor

H. Lee Moffitt Cancer Center and Research Institute

Collaborators

[object Object]
[object Object]